The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global HER2-Positive Breast Cancer Market Research Report 2025
Synopsis
HER2, also known as human epidermal growth factor receptor 2, is an important prognostic factor for breast cancer.HER2 is also expressed on the surface of some normal cells in the body.Her2-positive breast cancer is characterized by strong invasion, more recurrence and metastasis, and short disease-free survival.
The global HER2-Positive Breast Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for HER2-Positive Breast Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for HER2-Positive Breast Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for HER2-Positive Breast Cancer in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of HER2-Positive Breast Cancer include Pfizer (Pharmacia and Upjohn Company), Novartis, AstraZeneca Pharmaceuticals, Eli Lilly, Roche Group, Merck, Jiangsu HengRui Medicine, Odonate Therapeutics and Radius Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for HER2-Positive Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HER2-Positive Breast Cancer.
Report Scope
The HER2-Positive Breast Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HER2-Positive Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HER2-Positive Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer (Pharmacia and Upjohn Company)
Novartis
AstraZeneca Pharmaceuticals
Eli Lilly
Roche Group
Merck
Jiangsu HengRui Medicine
Odonate Therapeutics
Radius Pharmaceuticals
Immunomedics
Syndax Pharmaceuticals
Bayer
Eagle Pharmaceuticals
Merrimack Pharmaceuticals
GlaxoSmithKline
Millennium Pharmaceuticals
Segment by Type
Grifola Frondosa
Surgery
Radiation and Chemotherapy
Endocrine Therapy
Molecular Targeted Therapy
Segment by Application
Hospital
Specialist Clinic
Biotechnology and Pharmaceutical Companies
Research and Academic Institutions
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HER2-Positive Breast Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
HER2, also known as human epidermal growth factor receptor 2, is an important prognostic factor for breast cancer.HER2 is also expressed on the surface of some normal cells in the body.Her2-positive breast cancer is characterized by strong invasion, more recurrence and metastasis, and short disease-free survival.
The global HER2-Positive Breast Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for HER2-Positive Breast Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for HER2-Positive Breast Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for HER2-Positive Breast Cancer in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of HER2-Positive Breast Cancer include Pfizer (Pharmacia and Upjohn Company), Novartis, AstraZeneca Pharmaceuticals, Eli Lilly, Roche Group, Merck, Jiangsu HengRui Medicine, Odonate Therapeutics and Radius Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for HER2-Positive Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HER2-Positive Breast Cancer.
Report Scope
The HER2-Positive Breast Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HER2-Positive Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HER2-Positive Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer (Pharmacia and Upjohn Company)
Novartis
AstraZeneca Pharmaceuticals
Eli Lilly
Roche Group
Merck
Jiangsu HengRui Medicine
Odonate Therapeutics
Radius Pharmaceuticals
Immunomedics
Syndax Pharmaceuticals
Bayer
Eagle Pharmaceuticals
Merrimack Pharmaceuticals
GlaxoSmithKline
Millennium Pharmaceuticals
Segment by Type
Grifola Frondosa
Surgery
Radiation and Chemotherapy
Endocrine Therapy
Molecular Targeted Therapy
Segment by Application
Hospital
Specialist Clinic
Biotechnology and Pharmaceutical Companies
Research and Academic Institutions
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HER2-Positive Breast Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HER2-Positive Breast Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Grifola Frondosa
1.2.3 Surgery
1.2.4 Radiation and Chemotherapy
1.2.5 Endocrine Therapy
1.2.6 Molecular Targeted Therapy
1.3 Market by Application
1.3.1 Global HER2-Positive Breast Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Specialist Clinic
1.3.4 Biotechnology and Pharmaceutical Companies
1.3.5 Research and Academic Institutions
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global HER2-Positive Breast Cancer Market Perspective (2019-2030)
2.2 HER2-Positive Breast Cancer Growth Trends by Region
2.2.1 Global HER2-Positive Breast Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 HER2-Positive Breast Cancer Historic Market Size by Region (2019-2024)
2.2.3 HER2-Positive Breast Cancer Forecasted Market Size by Region (2025-2030)
2.3 HER2-Positive Breast Cancer Market Dynamics
2.3.1 HER2-Positive Breast Cancer Industry Trends
2.3.2 HER2-Positive Breast Cancer Market Drivers
2.3.3 HER2-Positive Breast Cancer Market Challenges
2.3.4 HER2-Positive Breast Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top HER2-Positive Breast Cancer Players by Revenue
3.1.1 Global Top HER2-Positive Breast Cancer Players by Revenue (2019-2024)
3.1.2 Global HER2-Positive Breast Cancer Revenue Market Share by Players (2019-2024)
3.2 Global HER2-Positive Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by HER2-Positive Breast Cancer Revenue
3.4 Global HER2-Positive Breast Cancer Market Concentration Ratio
3.4.1 Global HER2-Positive Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HER2-Positive Breast Cancer Revenue in 2023
3.5 HER2-Positive Breast Cancer Key Players Head office and Area Served
3.6 Key Players HER2-Positive Breast Cancer Product Solution and Service
3.7 Date of Enter into HER2-Positive Breast Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HER2-Positive Breast Cancer Breakdown Data by Type
4.1 Global HER2-Positive Breast Cancer Historic Market Size by Type (2019-2024)
4.2 Global HER2-Positive Breast Cancer Forecasted Market Size by Type (2025-2030)
5 HER2-Positive Breast Cancer Breakdown Data by Application
5.1 Global HER2-Positive Breast Cancer Historic Market Size by Application (2019-2024)
5.2 Global HER2-Positive Breast Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America HER2-Positive Breast Cancer Market Size (2019-2030)
6.2 North America HER2-Positive Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America HER2-Positive Breast Cancer Market Size by Country (2019-2024)
6.4 North America HER2-Positive Breast Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe HER2-Positive Breast Cancer Market Size (2019-2030)
7.2 Europe HER2-Positive Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe HER2-Positive Breast Cancer Market Size by Country (2019-2024)
7.4 Europe HER2-Positive Breast Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific HER2-Positive Breast Cancer Market Size (2019-2030)
8.2 Asia-Pacific HER2-Positive Breast Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America HER2-Positive Breast Cancer Market Size (2019-2030)
9.2 Latin America HER2-Positive Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America HER2-Positive Breast Cancer Market Size by Country (2019-2024)
9.4 Latin America HER2-Positive Breast Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa HER2-Positive Breast Cancer Market Size (2019-2030)
10.2 Middle East & Africa HER2-Positive Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer (Pharmacia and Upjohn Company)
11.1.1 Pfizer (Pharmacia and Upjohn Company) Company Detail
11.1.2 Pfizer (Pharmacia and Upjohn Company) Business Overview
11.1.3 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Introduction
11.1.4 Pfizer (Pharmacia and Upjohn Company) Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.1.5 Pfizer (Pharmacia and Upjohn Company) Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis HER2-Positive Breast Cancer Introduction
11.2.4 Novartis Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 AstraZeneca Pharmaceuticals
11.3.1 AstraZeneca Pharmaceuticals Company Detail
11.3.2 AstraZeneca Pharmaceuticals Business Overview
11.3.3 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.3.4 AstraZeneca Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.3.5 AstraZeneca Pharmaceuticals Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly HER2-Positive Breast Cancer Introduction
11.4.4 Eli Lilly Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.4.5 Eli Lilly Recent Development
11.5 Roche Group
11.5.1 Roche Group Company Detail
11.5.2 Roche Group Business Overview
11.5.3 Roche Group HER2-Positive Breast Cancer Introduction
11.5.4 Roche Group Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.5.5 Roche Group Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck HER2-Positive Breast Cancer Introduction
11.6.4 Merck Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Jiangsu HengRui Medicine
11.7.1 Jiangsu HengRui Medicine Company Detail
11.7.2 Jiangsu HengRui Medicine Business Overview
11.7.3 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Introduction
11.7.4 Jiangsu HengRui Medicine Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.7.5 Jiangsu HengRui Medicine Recent Development
11.8 Odonate Therapeutics
11.8.1 Odonate Therapeutics Company Detail
11.8.2 Odonate Therapeutics Business Overview
11.8.3 Odonate Therapeutics HER2-Positive Breast Cancer Introduction
11.8.4 Odonate Therapeutics Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.8.5 Odonate Therapeutics Recent Development
11.9 Radius Pharmaceuticals
11.9.1 Radius Pharmaceuticals Company Detail
11.9.2 Radius Pharmaceuticals Business Overview
11.9.3 Radius Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.9.4 Radius Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.9.5 Radius Pharmaceuticals Recent Development
11.10 Immunomedics
11.10.1 Immunomedics Company Detail
11.10.2 Immunomedics Business Overview
11.10.3 Immunomedics HER2-Positive Breast Cancer Introduction
11.10.4 Immunomedics Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.10.5 Immunomedics Recent Development
11.11 Syndax Pharmaceuticals
11.11.1 Syndax Pharmaceuticals Company Detail
11.11.2 Syndax Pharmaceuticals Business Overview
11.11.3 Syndax Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.11.4 Syndax Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.11.5 Syndax Pharmaceuticals Recent Development
11.12 Bayer
11.12.1 Bayer Company Detail
11.12.2 Bayer Business Overview
11.12.3 Bayer HER2-Positive Breast Cancer Introduction
11.12.4 Bayer Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.12.5 Bayer Recent Development
11.13 Eagle Pharmaceuticals
11.13.1 Eagle Pharmaceuticals Company Detail
11.13.2 Eagle Pharmaceuticals Business Overview
11.13.3 Eagle Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.13.4 Eagle Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.13.5 Eagle Pharmaceuticals Recent Development
11.14 Merrimack Pharmaceuticals
11.14.1 Merrimack Pharmaceuticals Company Detail
11.14.2 Merrimack Pharmaceuticals Business Overview
11.14.3 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.14.4 Merrimack Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.14.5 Merrimack Pharmaceuticals Recent Development
11.15 GlaxoSmithKline
11.15.1 GlaxoSmithKline Company Detail
11.15.2 GlaxoSmithKline Business Overview
11.15.3 GlaxoSmithKline HER2-Positive Breast Cancer Introduction
11.15.4 GlaxoSmithKline Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.15.5 GlaxoSmithKline Recent Development
11.16 Millennium Pharmaceuticals
11.16.1 Millennium Pharmaceuticals Company Detail
11.16.2 Millennium Pharmaceuticals Business Overview
11.16.3 Millennium Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.16.4 Millennium Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024)
11.16.5 Millennium Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global HER2-Positive Breast Cancer Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Grifola Frondosa
Table 3. Key Players of Surgery
Table 4. Key Players of Radiation and Chemotherapy
Table 5. Key Players of Endocrine Therapy
Table 6. Key Players of Molecular Targeted Therapy
Table 7. Global HER2-Positive Breast Cancer Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global HER2-Positive Breast Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global HER2-Positive Breast Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global HER2-Positive Breast Cancer Market Share by Region (2019-2024)
Table 11. Global HER2-Positive Breast Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global HER2-Positive Breast Cancer Market Share by Region (2025-2030)
Table 13. HER2-Positive Breast Cancer Market Trends
Table 14. HER2-Positive Breast Cancer Market Drivers
Table 15. HER2-Positive Breast Cancer Market Challenges
Table 16. HER2-Positive Breast Cancer Market Restraints
Table 17. Global HER2-Positive Breast Cancer Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global HER2-Positive Breast Cancer Market Share by Players (2019-2024)
Table 19. Global Top HER2-Positive Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HER2-Positive Breast Cancer as of 2023)
Table 20. Ranking of Global Top HER2-Positive Breast Cancer Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by HER2-Positive Breast Cancer Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players HER2-Positive Breast Cancer Product Solution and Service
Table 24. Date of Enter into HER2-Positive Breast Cancer Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global HER2-Positive Breast Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global HER2-Positive Breast Cancer Revenue Market Share by Type (2019-2024)
Table 28. Global HER2-Positive Breast Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global HER2-Positive Breast Cancer Revenue Market Share by Type (2025-2030)
Table 30. Global HER2-Positive Breast Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global HER2-Positive Breast Cancer Revenue Market Share by Application (2019-2024)
Table 32. Global HER2-Positive Breast Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global HER2-Positive Breast Cancer Revenue Market Share by Application (2025-2030)
Table 34. North America HER2-Positive Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America HER2-Positive Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America HER2-Positive Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe HER2-Positive Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe HER2-Positive Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe HER2-Positive Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific HER2-Positive Breast Cancer Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America HER2-Positive Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America HER2-Positive Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America HER2-Positive Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa HER2-Positive Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 49. Pfizer (Pharmacia and Upjohn Company) Company Detail
Table 50. Pfizer (Pharmacia and Upjohn Company) Business Overview
Table 51. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product
Table 52. Pfizer (Pharmacia and Upjohn Company) Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 53. Pfizer (Pharmacia and Upjohn Company) Recent Development
Table 54. Novartis Company Detail
Table 55. Novartis Business Overview
Table 56. Novartis HER2-Positive Breast Cancer Product
Table 57. Novartis Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 58. Novartis Recent Development
Table 59. AstraZeneca Pharmaceuticals Company Detail
Table 60. AstraZeneca Pharmaceuticals Business Overview
Table 61. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product
Table 62. AstraZeneca Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 63. AstraZeneca Pharmaceuticals Recent Development
Table 64. Eli Lilly Company Detail
Table 65. Eli Lilly Business Overview
Table 66. Eli Lilly HER2-Positive Breast Cancer Product
Table 67. Eli Lilly Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 68. Eli Lilly Recent Development
Table 69. Roche Group Company Detail
Table 70. Roche Group Business Overview
Table 71. Roche Group HER2-Positive Breast Cancer Product
Table 72. Roche Group Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 73. Roche Group Recent Development
Table 74. Merck Company Detail
Table 75. Merck Business Overview
Table 76. Merck HER2-Positive Breast Cancer Product
Table 77. Merck Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 78. Merck Recent Development
Table 79. Jiangsu HengRui Medicine Company Detail
Table 80. Jiangsu HengRui Medicine Business Overview
Table 81. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product
Table 82. Jiangsu HengRui Medicine Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 83. Jiangsu HengRui Medicine Recent Development
Table 84. Odonate Therapeutics Company Detail
Table 85. Odonate Therapeutics Business Overview
Table 86. Odonate Therapeutics HER2-Positive Breast Cancer Product
Table 87. Odonate Therapeutics Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 88. Odonate Therapeutics Recent Development
Table 89. Radius Pharmaceuticals Company Detail
Table 90. Radius Pharmaceuticals Business Overview
Table 91. Radius Pharmaceuticals HER2-Positive Breast Cancer Product
Table 92. Radius Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 93. Radius Pharmaceuticals Recent Development
Table 94. Immunomedics Company Detail
Table 95. Immunomedics Business Overview
Table 96. Immunomedics HER2-Positive Breast Cancer Product
Table 97. Immunomedics Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 98. Immunomedics Recent Development
Table 99. Syndax Pharmaceuticals Company Detail
Table 100. Syndax Pharmaceuticals Business Overview
Table 101. Syndax Pharmaceuticals HER2-Positive Breast Cancer Product
Table 102. Syndax Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 103. Syndax Pharmaceuticals Recent Development
Table 104. Bayer Company Detail
Table 105. Bayer Business Overview
Table 106. Bayer HER2-Positive Breast Cancer Product
Table 107. Bayer Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 108. Bayer Recent Development
Table 109. Eagle Pharmaceuticals Company Detail
Table 110. Eagle Pharmaceuticals Business Overview
Table 111. Eagle Pharmaceuticals HER2-Positive Breast Cancer Product
Table 112. Eagle Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 113. Eagle Pharmaceuticals Recent Development
Table 114. Merrimack Pharmaceuticals Company Detail
Table 115. Merrimack Pharmaceuticals Business Overview
Table 116. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product
Table 117. Merrimack Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 118. Merrimack Pharmaceuticals Recent Development
Table 119. GlaxoSmithKline Company Detail
Table 120. GlaxoSmithKline Business Overview
Table 121. GlaxoSmithKline HER2-Positive Breast Cancer Product
Table 122. GlaxoSmithKline Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 123. GlaxoSmithKline Recent Development
Table 124. Millennium Pharmaceuticals Company Detail
Table 125. Millennium Pharmaceuticals Business Overview
Table 126. Millennium Pharmaceuticals HER2-Positive Breast Cancer Product
Table 127. Millennium Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2019-2024) & (US$ Million)
Table 128. Millennium Pharmaceuticals Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global HER2-Positive Breast Cancer Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global HER2-Positive Breast Cancer Market Share by Type: 2023 VS 2030
Figure 3. Grifola Frondosa Features
Figure 4. Surgery Features
Figure 5. Radiation and Chemotherapy Features
Figure 6. Endocrine Therapy Features
Figure 7. Molecular Targeted Therapy Features
Figure 8. Global HER2-Positive Breast Cancer Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global HER2-Positive Breast Cancer Market Share by Application: 2023 VS 2030
Figure 10. Hospital Case Studies
Figure 11. Specialist Clinic Case Studies
Figure 12. Biotechnology and Pharmaceutical Companies Case Studies
Figure 13. Research and Academic Institutions Case Studies
Figure 14. Other Case Studies
Figure 15. HER2-Positive Breast Cancer Report Years Considered
Figure 16. Global HER2-Positive Breast Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global HER2-Positive Breast Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global HER2-Positive Breast Cancer Market Share by Region: 2023 VS 2030
Figure 19. Global HER2-Positive Breast Cancer Market Share by Players in 2023
Figure 20. Global Top HER2-Positive Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HER2-Positive Breast Cancer as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by HER2-Positive Breast Cancer Revenue in 2023
Figure 22. North America HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America HER2-Positive Breast Cancer Market Share by Country (2019-2030)
Figure 24. United States HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe HER2-Positive Breast Cancer Market Share by Country (2019-2030)
Figure 28. Germany HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific HER2-Positive Breast Cancer Market Share by Region (2019-2030)
Figure 36. China HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America HER2-Positive Breast Cancer Market Share by Country (2019-2030)
Figure 44. Mexico HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa HER2-Positive Breast Cancer Market Share by Country (2019-2030)
Figure 48. Turkey HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia HER2-Positive Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Pfizer (Pharmacia and Upjohn Company) Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 51. Novartis Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 52. AstraZeneca Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 53. Eli Lilly Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 54. Roche Group Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 55. Merck Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 56. Jiangsu HengRui Medicine Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 57. Odonate Therapeutics Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 58. Radius Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 59. Immunomedics Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 60. Syndax Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 61. Bayer Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 62. Eagle Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 63. Merrimack Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 64. GlaxoSmithKline Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 65. Millennium Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2019-2024)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
